Evidence map›Paper›PMID 32047816›Full record

ArticleBioMed research international2020

Screening and Identification of Key Biomarkers for Bladder Cancer: A Study Based on TCGA and GEO Data.

Yingkun Xu, Guangzhen Wu, Jianyi Li, Jiatong Li, Ningke Ruan, Liye Ma, Xiaoyang Han, Yanjun Wei, Liang Li, Hongge Zhang and 2 more

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Pharmaceuticals (Basel, Switzerland) · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. ScreeningFrontiers in genetics · 2023
    Article
  16. Article
  17. Analysis of prognostic oncogene filaggrin (Translational andrology and urology · 2022
    Article
  18. Article
  19. Cancers · 2022
    Article
  20. The 1q21.3 region driver geneTranslational cancer research · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Yingkun XuDepartment of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Guangzhen WuDepartment of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.ORCID https://orcid.org/0000-0002-2300-8465
Jianyi LiDepartment of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Jiatong LiDepartment of Nephrology, Shandong Provincial Hospital, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan, China.
Ningke RuanThe Nursing College of Zhengzhou University, Zhengzhou, China.
Liye MaDepartment of Liver Transplantation and Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Xiaoyang HanDepartment of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Yanjun WeiDepartment of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Liang LiShangdong Academy of Medical Sciences, Jinan University, Jinan, China.
Hongge ZhangDepartment of Urology, Tengzhou Hospital of Traditional Chinese Medicine, Tengzhou, China.
Yougen ChenDepartment of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Qinghua XiaDepartment of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.ORCID https://orcid.org/0000-0002-8261-6014
Shandong University · CNDalian Medical University · CNJinan University · CNTengzhou Central People's Hospital · CNZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bladder cancer (BLCA) is a common malignant cancer, and it is the most common genitourinary cancer in the world. The recurrence rate is the highest of all cancers, and the treatment of BLCA has only slightly improved over the past 30 years. Genetic and environmental factors play an important role in the development and progression of BLCA. However, the mechanism of cancer development remains to be proven. Therefore, the identification of potential oncogenes is urgent for developing new therapeutic directions and designing novel biomarkers for the diagnosis and prognosis of BLCA. Based on this need, we screened overlapping differentially expressed genes (DEG) from the GSE7476, GSE13507, and TCGA BLCA datasets. To identify the central genes from these DEGs, we performed a protein-protein interaction network analysis. To investigate the role of DEGs and the underlying mechanisms in BLCA, we performed Gene Ontology (GO) and Kyoto Gene and Genomic Encyclopedia (KEGG) analysis; we identified the hub genes via different evaluation methods in cytoHubba and then selected the target genes by performing survival analysis. Finally, the relationship between these target genes and tumour immunity was analysed to explore the roles of these genes. In summary, our current studies indicate that both cell division cycle 20 (CDC20) and abnormal spindle microtubule assembly (ASPM) genes are potential prognostic biomarkers for BLCA. It may also be a potential immunotherapeutic target with future clinical significance.

Indexed as

Biomarkers, TumorCdc20 ProteinsCell Line, TumorCell ProliferationCell SurvivalEarly Detection of CancerGene Expression ProfilingGene Expression Regulation, NeoplasticGene OntologyHumansNerve Tissue ProteinsPrognosisProtein Interaction MapsRNA, MessengerSurvival AnalysisUrinary Bladder NeoplasmsASPM protein, humanBiomarkers, TumorCDC20 protein, humanCdc20 ProteinsNerve Tissue ProteinsRNA, Messenger

Identifiers

PMID32047816
PMCPMC7003274
OpenAlexW3001922428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.